Rchr
J-GLOBAL ID：201801013802384664
Update date: Dec. 09, 2024
Fukushima Kentaro
Fukushima Kentaro
Affiliation and department：
Research field (1)：
Hematology and oncology
Research theme for competitive and other funds (3)：
- 2023 - 2026 造血細胞移植の予後および合併症リスクを規定する腸内細菌叢関連因子の探索
- 2013 - 2016 Anti-inflammatory sFRP5 inhibits early B-lymphopoiesis in vivo
- 2010 - 2012 The molecular mechanism of prognostic exacerbation by the addition of KIT mutations in CBF leukemia
Papers (112)：
-
Tansri Wibowo, Yosuke Kogue, Shunya Ikeda, Moto Yaga, Mana Tachikawa, Makiko Suga, Shuhei Kida, Kumi Shibata, Kazuhito Tsutsumi, Hiraku Murakami, et al. CAR-NK cells derived from cord blood originate mainly from CD56-CD7+CD34-HLA-DR-Lin- NK progenitor cells. Molecular Therapy Methods and Clinical Development. 2024. 32. 4
-
Souichi Shiratori, Kentaro Fukushima, Yasushi Onishi, Noriko Doki, Tatsunori Goto, Masaya Okada, Hirohisa Nakamae, Yoshinobu Maeda, Koji Kato, Takayuki Ishikawa, et al. Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study. International journal of hematology. 2024. 120. 6. 705-716
-
Atsushi Marumo, Yasunobu Nagata, Machiko Fujioka, Shuhei Kurosawa, Yuho Najima, Emiko Sakaida, Noriko Doki, Kentaro Fukushima, Shuichi Ota, Katsuhiro Shono, et al. Outcome of donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation in relapsed myelodysplastic syndrome. Cytotherapy. 2024
-
Tomoyasu Jo, Kyoko Yoshihara, Masaki Ri, Nobuhiro Tsukada, Naoya Mimura, Keiko Fujii, Kentaro Fukushima, Shin-ichiro Fujiwara, Yuji Shimura, Kyoko Haraguchi, et al. Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma. Blood Neoplasia. 2024. 100051-100051
-
Yo Mizutani, Tomoaki Ueda, Jiro Fujita, Kentaro Fukushima, Naoki Hosen. Ibrutinib as a Secondary Treatment for Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease: A Case Series of 11 Patients During the COVID-19 Era. Cureus. 2024. 16. 10. e71474
ｍore...
MISC (42)：
-
水谷陽, 草壁信輔, 福島健太郎, 村上拓, 濱田雅隆, 長谷川千紘, 水田惠美子, 山口優太, 中井りつこ, 倉重隆明, et al. Sequential therapy of Inotuzumab ozogamicin and CAR-T for Ph-negative acute lymphoblastic leukemia. 日本造血・免疫細胞療法学会総会プログラム・抄録集. 2024. 46th
-
竹原経子, 福島健太郎, 水谷陽, 長谷川千紘, 水田恵美子, 山口優太, 倉重隆明, 中井りつこ, 日野彬央, 草壁真輔, et al. Evaluation of quality of life and symptoms after hematopoietic stem cell transplantation. 日本造血・免疫細胞療法学会総会プログラム・抄録集. 2024. 46th
-
水田惠美子, 福島健太郎, 濱田雅隆, 水谷陽, 長谷川千紘, 山口優太, 中井りつ子, 倉重隆明, 日野彬央, 草壁信輔, et al. Analysis of HSCT for myelofibrosis treated with pre-and post-transplant ruxolitinib. 日本造血・免疫細胞療法学会総会プログラム・抄録集. 2024. 46th
-
水田惠美子, 福島健太郎, 濱田雅隆, 水谷陽, 長谷川千紘, 山口優太, 倉重隆明, 日野彬央, 草壁信輔, 上田智明, et al. Experience of ide-cel use in relapsed/refractory multiple myeloma at our institution. International Journal of Myeloma (Web). 2024. 14. 3
-
遠藤誉也, 日野彬央, 草壁信輔, 上田智朗, 数藤孝雄, 藤田二郎, 福島健太郎, 保仙直毅. 血液透析中の患者に対し移植後シクロホスファミド併用末梢血幹細胞移植を施行した1例. 臨床血液. 2023. 64. 8
ｍore...
Work history (2)：
- 2022/04 - 現在 Osaka University
- 2017/09 - 2022/03 大阪大学大学院医学系研究科 血液・腫瘍内科学 助教
Return to Previous Page
